Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash & Current Investments (2016 - 2026)

Theravance Biopharma has reported Cash & Current Investments over the past 12 years, most recently at $315.4 million for Q4 2025.

  • Quarterly Cash & Current Investments rose 256.94% to $315.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $315.4 million through Dec 2025, up 256.94% year-over-year, with the annual reading at $315.4 million for FY2025, 256.94% up from the prior year.
  • Cash & Current Investments was $315.4 million for Q4 2025 at Theravance Biopharma, up from $177.2 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $486.8 million in Q3 2022 and troughed at $88.4 million in Q4 2024.
  • The 5-year median for Cash & Current Investments is $170.5 million (2021), against an average of $197.1 million.
  • Year-over-year, Cash & Current Investments tumbled 72.47% in 2023 and then surged 256.94% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $173.5 million in 2021, then soared by 88.79% to $327.5 million in 2022, then tumbled by 68.72% to $102.4 million in 2023, then decreased by 13.74% to $88.4 million in 2024, then surged by 256.94% to $315.4 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Cash & Current Investments are $315.4 million (Q4 2025), $177.2 million (Q3 2025), and $338.8 million (Q2 2025).